Furthermore, we demonstrate that co-administration of BRAF and MEK inhibitors improves both the safety, by reducing the occurrence of skin lesions, and the in vivo activity profile, by reducing tumor regrowth, over that of a BRAF inhibitor alone in rodents. The gene discussed is BRAF; the disease is neoplasm.